The laboratory verification device in a cartridge, which can be performed next to the patient’s bed, does not require a laboratory and can be made in cartridges smaller than a cell phone, has been verified in 386 by the National Health Service and patients in Britain. .
The control had a sensitivity of 94% and a specificity of one hundred percent, which means that it had a maximum point of accuracy and produced very few false negatives and no false positives. The effects should be obtained in 90 minutes, while the traditional COVID -19 controls supply effects in 24 hours, the researchers said. The effects were published on September 17 on The Lancet Microbe.
In the United States, 4 immediate coronavirus tests have already been developed, which run into COVID-19 antigens, proteins discovered on the surface of the coronavirus, than with the virus itself, according to the Associated Press. even less accurate detection approach.
One such test, conducted through Abbott Laboratories and called BinaxNOW, has already reached a $760 million deal with the White House to produce 150 million nasal swab tests for network testing, according to the AP.
The 15-minute BinaxNOW check will sell for $5, giving you credit for checks that want to be inserted into a small machine, AP reported. No larger than a credit card, the Abbott check is based on the same generation used for checks. flu, strep throat and other infections.
“These [fast] drug tests are what we want in schools, workplaces, and nursing homes to detect asymptomatic contagions,” Dr Jonathan Quick, an assistant global health professor, told the AP. Duke University in North Carolina.
With the British test, a patient’s nasal swab is inserted into the cartridge device, which analyzes the genetic pattern that belongs to the SARS-CoV-2 virus.
The new one is being used in 8 london hospitals and is expected to be implemented nationwide. The BRITISH government recently ordered 5. 8 million kits.
“These effects recommend that the test, which can be performed next to a patient’s bedside without the desire to care for any samples, has accuracy comparable to that of popular laboratory tests,” said examiner Graham Cooke, professor at the Department of Infectious Diseases at Imperial College London.
“Many checks involve compensation between speed and accuracy, but this verification manages for both,” Cooke said in a university press release.
The verification, carried out through DnaNudge, a start-up company at Imperial College London, is recently being developed to verify COVID-19, influenza and respiratory syncytial virus, the researchers added.